Coherus BioSciences Inc. (CHRS)’s Financial Results Comparing With Xenetic Biosciences Inc. (NASDAQ:XBIO)

Since Coherus BioSciences Inc. (NASDAQ:CHRS) and Xenetic Biosciences Inc. (NASDAQ:XBIO) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. 37.10M 34.87 185.05M -3.11 0.00
Xenetic Biosciences Inc. N/A 0.00 10.68M -0.81 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows Coherus BioSciences Inc. and Xenetic Biosciences Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. -498.79% 0% -120.3%
Xenetic Biosciences Inc. 0.00% -62.3% -45.1%

Risk & Volatility

Coherus BioSciences Inc.’s volatility measures that it’s 259.00% more volatile than S&P 500 due to its 3.59 beta. Xenetic Biosciences Inc. on the other hand, has 2.1 beta which makes it 110.00% more volatile compared to S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Coherus BioSciences Inc. are 3.8 and 3.8. Competitively, Xenetic Biosciences Inc. has 0.7 and 0.7 for Current and Quick Ratio. Coherus BioSciences Inc.’s better ability to pay short and long-term obligations than Xenetic Biosciences Inc.

Analyst Recommendations

In next table is given Coherus BioSciences Inc. and Xenetic Biosciences Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 2 3.00
Xenetic Biosciences Inc. 0 0 0 0.00

Coherus BioSciences Inc. has a 34.05% upside potential and a consensus price target of $25.

Institutional & Insider Ownership

Roughly 99.1% of Coherus BioSciences Inc. shares are owned by institutional investors while 11% of Xenetic Biosciences Inc. are owned by institutional investors. Insiders owned 0.3% of Coherus BioSciences Inc. shares. Insiders Competitively, owned 58.2% of Xenetic Biosciences Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. 6.64% 15.6% 20.46% 70.96% 2.63% 89.94%
Xenetic Biosciences Inc. -10.37% -23.4% -40.46% -54.18% -34.6% -26.22%

For the past year Coherus BioSciences Inc. had bullish trend while Xenetic Biosciences Inc. had bearish trend.

Summary

Coherus BioSciences Inc. beats on 6 of the 10 factors Xenetic Biosciences Inc.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.